Treating AML in Older Adults, with Dr. Timothy Pardee
Dr. Timothy Pardee discusses treatments for AML, or
IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
Dr. Timothy Pardee discusses treatments for AML, or
Dr. Allyson Pishko shares the latest advances in the treatment of PNH, or
Dr. Nandita Khera discusses why and when transplants can be recommended for older patients in this podcast episode.
Dr. Rory Shallis discusses a variety of current treatments for MDS, or Myelodysplastic Syndromes
Dr. Jacqueline Garcia discusses the use of hypomenthylating agents.
Key Points
Itacitinib monotherapy is as effective as systemic corticosteroids for the treatment of low risk acute GVHD.
Itacitinib monotherapy resulted in fewer serious infections compared to systemic corticosteroids.
Find links to the recordings from the sessions at the 2022 Patient and Family Hybrid Conference below.
BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.